FR2459240A1 - Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent - Google Patents
Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent Download PDFInfo
- Publication number
- FR2459240A1 FR2459240A1 FR7915974A FR7915974A FR2459240A1 FR 2459240 A1 FR2459240 A1 FR 2459240A1 FR 7915974 A FR7915974 A FR 7915974A FR 7915974 A FR7915974 A FR 7915974A FR 2459240 A1 FR2459240 A1 FR 2459240A1
- Authority
- FR
- France
- Prior art keywords
- group
- pyridyl
- amino
- piperidine
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000008569 process Effects 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 239000000543 intermediate Substances 0.000 title description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 11
- 150000002367 halogens Chemical class 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 12
- CZINLSYKXBADTA-UHFFFAOYSA-N 1-pyridin-2-ylpiperidin-4-amine Chemical class C1CC(N)CCN1C1=CC=CC=N1 CZINLSYKXBADTA-UHFFFAOYSA-N 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- YLWUSMHZABTZGP-UHFFFAOYSA-N n-piperidin-4-ylacetamide Chemical compound CC(=O)NC1CCNCC1 YLWUSMHZABTZGP-UHFFFAOYSA-N 0.000 claims description 8
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims description 4
- WPVVMKYQOMJPIN-UHFFFAOYSA-N 1-(6-chloro-2-pyridinyl)-4-piperidinamine Chemical compound C1CC(N)CCN1C1=CC=CC(Cl)=N1 WPVVMKYQOMJPIN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 3
- 150000005749 2-halopyridines Chemical class 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- FUMINTAAUJUVMP-UHFFFAOYSA-N 1-(6-chloropyridin-2-yl)piperidin-4-amine;hydron;chloride Chemical compound Cl.C1CC(N)CCN1C1=CC=CC(Cl)=N1 FUMINTAAUJUVMP-UHFFFAOYSA-N 0.000 claims description 2
- UVZFVSNJAQJYCQ-UHFFFAOYSA-N 1-(6-methoxypyridin-2-yl)piperidin-4-amine;hydrochloride Chemical compound Cl.COC1=CC=CC(N2CCC(N)CC2)=N1 UVZFVSNJAQJYCQ-UHFFFAOYSA-N 0.000 claims description 2
- FHBCTQQQTPYSTA-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)piperidin-4-amine;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC(N2CCC(N)CC2)=N1 FHBCTQQQTPYSTA-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- SGLJQTKFRSTKLJ-UHFFFAOYSA-N 1-(6-bromopyridin-2-yl)piperidin-4-amine;hydrochloride Chemical compound Cl.C1CC(N)CCN1C1=CC=CC(Br)=N1 SGLJQTKFRSTKLJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- -1 2-PYRIDYL Chemical class 0.000 abstract description 15
- 230000009471 action Effects 0.000 abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000006742 locomotor activity Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000001539 anorectic effect Effects 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 230000002891 anorexigenic effect Effects 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229960001582 fenfluramine Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- AJEUJXWLOADTKA-UHFFFAOYSA-N 2-piperidin-1-ylpyridine Chemical class C1CCCCN1C1=CC=CC=N1 AJEUJXWLOADTKA-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- OLFSWZFZIXYBQA-UHFFFAOYSA-N n-(1-pyridin-2-ylpiperidin-4-yl)acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=CC=N1 OLFSWZFZIXYBQA-UHFFFAOYSA-N 0.000 description 3
- BIJAWQUBRNHZGE-UHFFFAOYSA-N n-pyridin-4-ylacetamide Chemical compound CC(=O)NC1=CC=NC=C1 BIJAWQUBRNHZGE-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- KQFRTJUIRPBBAB-UHFFFAOYSA-N 1-(6-chloropyridin-2-yl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=N1 KQFRTJUIRPBBAB-UHFFFAOYSA-N 0.000 description 2
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 2
- CJAWPFJGFFNXQI-UHFFFAOYSA-N 2-chloro-6-(1-piperazinyl)pyrazine Chemical compound ClC1=CN=CC(N2CCNCC2)=N1 CJAWPFJGFFNXQI-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- MXKALRMOISVVET-UHFFFAOYSA-N n-[1-(6-bromopyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=CC(Br)=N1 MXKALRMOISVVET-UHFFFAOYSA-N 0.000 description 2
- GRYSTXPEXZXOPG-UHFFFAOYSA-N n-[2-(6-phenoxypyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1C(NC(=O)C)CCNC1C1=CC=CC(OC=2C=CC=CC=2)=N1 GRYSTXPEXZXOPG-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NOSKSNWYGYGGBH-UHFFFAOYSA-N 1-(3-chloropyridin-2-yl)piperidin-4-amine;hydrochloride Chemical compound Cl.C1CC(N)CCN1C1=NC=CC=C1Cl NOSKSNWYGYGGBH-UHFFFAOYSA-N 0.000 description 1
- FEYDZHNIIMENOB-UHFFFAOYSA-N 2,6-dibromopyridine Chemical compound BrC1=CC=CC(Br)=N1 FEYDZHNIIMENOB-UHFFFAOYSA-N 0.000 description 1
- NAMSUQXNPIXZQF-UHFFFAOYSA-N 2-chloro-6-(2,2,2-trifluoroethoxy)pyridine Chemical compound FC(F)(F)COC1=CC=CC(Cl)=N1 NAMSUQXNPIXZQF-UHFFFAOYSA-N 0.000 description 1
- VAVGOGHLNAJECD-UHFFFAOYSA-N 2-chloro-6-methoxypyridine Chemical compound COC1=CC=CC(Cl)=N1 VAVGOGHLNAJECD-UHFFFAOYSA-N 0.000 description 1
- WTAURALGPQDIDB-UHFFFAOYSA-N 2-chloro-6-methylpyridine Chemical compound CC1=C[C]=CC(Cl)=N1 WTAURALGPQDIDB-UHFFFAOYSA-N 0.000 description 1
- FTBCXEHMCFPRRF-UHFFFAOYSA-N 2-chloro-6-phenoxypyridine Chemical compound ClC1=CC=CC(OC=2C=CC=CC=2)=N1 FTBCXEHMCFPRRF-UHFFFAOYSA-N 0.000 description 1
- JRPFESQQRLEKBN-UHFFFAOYSA-N 2-chloro-6-phenylsulfanylpyridine Chemical compound ClC1=CC=CC(SC=2C=CC=CC=2)=N1 JRPFESQQRLEKBN-UHFFFAOYSA-N 0.000 description 1
- RLCPWOMTHWJBGU-UHFFFAOYSA-N 2-chloro-6-piperidin-1-ylpyridine Chemical compound ClC1=CC=CC(N2CCCCC2)=N1 RLCPWOMTHWJBGU-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- NGZXGTKDXPFBSQ-UHFFFAOYSA-N 2-propan-2-ylsulfanylpyridine Chemical compound CC(C)SC1=CC=CC=N1 NGZXGTKDXPFBSQ-UHFFFAOYSA-N 0.000 description 1
- 150000003928 4-aminopyridines Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- YYQMYFOHVPGXFS-UHFFFAOYSA-N Cl.NC1CC(NCC1)C1=NC(=CC=C1)OC1=CC=CC=C1 Chemical compound Cl.NC1CC(NCC1)C1=NC(=CC=C1)OC1=CC=CC=C1 YYQMYFOHVPGXFS-UHFFFAOYSA-N 0.000 description 1
- HVLBNWOVUBONEG-UHFFFAOYSA-N Cl.NC1CCN(CC1)C1=NC(=CC=C1)SC1=CC=CC=C1 Chemical compound Cl.NC1CCN(CC1)C1=NC(=CC=C1)SC1=CC=CC=C1 HVLBNWOVUBONEG-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 229940124332 anorexigenic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- CXEJLCGIRISACP-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)formamide Chemical compound C1CC(NC=O)CCN1CC1=CC=CC=C1 CXEJLCGIRISACP-UHFFFAOYSA-N 0.000 description 1
- IMFINBLMVWTWQX-UHFFFAOYSA-N n-[1-(6-chloropyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=CC(Cl)=N1 IMFINBLMVWTWQX-UHFFFAOYSA-N 0.000 description 1
- MQBHRQVKQODGLJ-UHFFFAOYSA-N n-[1-(6-methoxypyridin-2-yl)piperidin-4-yl]acetamide Chemical compound COC1=CC=CC(N2CCC(CC2)NC(C)=O)=N1 MQBHRQVKQODGLJ-UHFFFAOYSA-N 0.000 description 1
- WDOWZTLOVXPBHR-UHFFFAOYSA-N n-[1-(6-phenylsulfanylpyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=CC(SC=2C=CC=CC=2)=N1 WDOWZTLOVXPBHR-UHFFFAOYSA-N 0.000 description 1
- OVFHYSUFZYZAEA-UHFFFAOYSA-N n-[1-[6-(2,2,2-trifluoroethoxy)pyridin-2-yl]piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=CC(OCC(F)(F)F)=N1 OVFHYSUFZYZAEA-UHFFFAOYSA-N 0.000 description 1
- NLTYRNPXSYWTID-UHFFFAOYSA-N n-[2-(3-chloropyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1C(NC(=O)C)CCNC1C1=NC=CC=C1Cl NLTYRNPXSYWTID-UHFFFAOYSA-N 0.000 description 1
- VXPPKXMXWAXARF-UHFFFAOYSA-N n-[2-(6-phenylsulfanylpyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1C(NC(=O)C)CCNC1C1=CC=CC(SC=2C=CC=CC=2)=N1 VXPPKXMXWAXARF-UHFFFAOYSA-N 0.000 description 1
- SXESBRNYONQKLV-UHFFFAOYSA-N n-piperidin-1-ylacetamide Chemical compound CC(=O)NN1CCCCC1 SXESBRNYONQKLV-UHFFFAOYSA-N 0.000 description 1
- QQWXHHWNGQDRCX-UHFFFAOYSA-N n-piperidin-4-ylformamide Chemical compound O=CNC1CCNCC1 QQWXHHWNGQDRCX-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PFWWZGINJSDVGU-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1.C1CCNCC1 PFWWZGINJSDVGU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 231100000316 potential neurotoxicity Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- MSGMXYUAWZYTFC-UHFFFAOYSA-N sodium;2,2,2-trifluoroethanolate Chemical compound [Na+].[O-]CC(F)(F)F MSGMXYUAWZYTFC-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7915974A FR2459240A1 (fr) | 1979-06-21 | 1979-06-21 | Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent |
| ES492484A ES492484A0 (es) | 1979-06-21 | 1980-06-16 | Procedimiento para la preparacion de 4-amino-1-(2-piridil) piperidinas |
| DE8181107653T DE3065220D1 (en) | 1979-06-21 | 1980-06-17 | Compounds useful in the preparation of aminopiperidines with anorectic properties |
| DE8080400874T DE3061266D1 (en) | 1979-06-21 | 1980-06-17 | Anorectic amino piperidines, process for their preparation and medicaments containing them |
| EP81107653A EP0045980B1 (fr) | 1979-06-21 | 1980-06-17 | Composés utiles notamment pour la préparation d'aminopipéridines ayant des propriétés anorexigènes |
| AT81107653T ATE4901T1 (de) | 1979-06-21 | 1980-06-17 | Fuer die herstellung von aminopiperidinen mit appetithemmender wirkung nuetzliche verbindungen. |
| EP80400874A EP0021973B1 (fr) | 1979-06-21 | 1980-06-17 | Aminopipéridines anorexigènes, procédé pour leur préparation et médicaments les contenant |
| AT80400874T ATE1930T1 (de) | 1979-06-21 | 1980-06-17 | Appetithemmende aminopiperidine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel. |
| CA000354142A CA1142936A (en) | 1979-06-21 | 1980-06-17 | 4-amino-1-(2-pyridyl)piperidine compounds |
| AR281448A AR229088A1 (es) | 1979-06-21 | 1980-06-18 | Procedimiento para preparar nuevas aminopiperidinas que tienen una actividad anorexica |
| MX10144180U MX6113E (es) | 1979-06-21 | 1980-06-18 | Procedimiento para preparar 4-amino-1-(2-piridil)-piperidinas |
| JP8300880A JPS5636481A (en) | 1979-06-21 | 1980-06-20 | Aminopiperidine* its manufacture* intermediate and medicine |
| US06/327,022 US4409228A (en) | 1979-06-21 | 1981-12-03 | Andrexiant aminopiperidines intermediates thereto and drugs containing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7915974A FR2459240A1 (fr) | 1979-06-21 | 1979-06-21 | Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2459240A1 true FR2459240A1 (fr) | 1981-01-09 |
| FR2459240B1 FR2459240B1 (cg-RX-API-DMAC10.html) | 1982-10-22 |
Family
ID=9226937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7915974A Granted FR2459240A1 (fr) | 1979-06-21 | 1979-06-21 | Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4409228A (cg-RX-API-DMAC10.html) |
| EP (2) | EP0021973B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JPS5636481A (cg-RX-API-DMAC10.html) |
| AR (1) | AR229088A1 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE4901T1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA1142936A (cg-RX-API-DMAC10.html) |
| DE (1) | DE3061266D1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES492484A0 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2459240A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
| GB8710494D0 (en) * | 1987-05-02 | 1987-06-03 | Pfizer Ltd | Antiarrhythmic agents |
| FR2674435B1 (fr) * | 1991-03-27 | 1995-03-10 | Sanofi Elf | Utilisation de 4-amino-1-(2-pyridyl) piperidines pour la preparation d'agents psychotropes. |
| SG47477A1 (en) * | 1991-03-27 | 1998-04-17 | Sanofi Sa | Use of 4-amino-1-(2-pyridyl)piperidines for the preparation of medicaments for the treatment and prophylaxis of conditions deriving from a dysfunctioning of |
| FR2674752B1 (fr) * | 1991-09-03 | 1995-03-10 | Sanofi Elf | Utilisation de 4-amino-1-(2-pyridyl)piperidines pour la preparation de medicaments pour le traitement et la prophylaxie des etats decoulant d'un dysfonctionnement du systeme serotoninergique. |
| FR2681785B1 (fr) * | 1991-09-30 | 1995-05-24 | Sanofi Elf | Utilisation de 4-amino-1-(2-pyridyl)piperidines en tant qu'agents anticonvulsivants et antiepileptiques. |
| AU674207B2 (en) * | 1993-04-07 | 1996-12-12 | Otsuka Pharmaceutical Co., Ltd. | N-acylated 4-amino piperidine derivatives |
| US6632823B1 (en) * | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| US6833370B1 (en) | 1999-05-21 | 2004-12-21 | Abbott Laboratories | Heterocycle substituted aminoazacycles useful as central nervous system agents |
| KR100713572B1 (ko) * | 1999-05-21 | 2007-05-02 | 아보트 러보러터리즈 | 중추 신경계 제제로서 유용한 헤테로사이클릭 치환된 아미노아자사이클 및 이를 포함하는 약제학적 조성물 |
| CZ20014127A3 (cs) | 1999-05-21 | 2002-06-12 | Abbott Laboratories | Heterocyklické substituované aminoazacykly uľitečné jako prostředky ovlivňující centrální nervový systém |
| KR100715344B1 (ko) * | 1999-11-23 | 2007-05-08 | 얀센 파마슈티카 엔.브이. | 기저부 이완을 위한 5ｈｔ3 효능제의 용도 |
| WO2001053288A1 (en) | 2000-01-20 | 2001-07-26 | Eisai Co., Ltd. | Novel piperidine compounds and drugs containing the same |
| TW200738672A (en) * | 2001-12-10 | 2007-10-16 | Bristol Myers Squibb Co | Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| RU2457209C2 (ru) | 2006-04-21 | 2012-07-27 | Новартис Аг | Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а |
| CN102452978A (zh) * | 2010-11-01 | 2012-05-16 | 重庆康丁医药技术有限公司 | 2-氯-取代或未取代脂族烃氧基吡啶及其制备方法 |
| EP3646886B1 (en) | 2017-06-28 | 2023-10-04 | Osaka University | Treatment of pain with serotonin-3 receptor agonist |
| TW202508584A (zh) | 2023-05-25 | 2025-03-01 | 日商丸石製藥股份有限公司 | 癌性疼痛預防或治療用組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE738495C (de) * | 1941-08-10 | 1943-08-18 | Kastel Tvornica Kemijsko Farma | Verfahren zur Darstellung von substituierten 4-Aminopiperidinen |
-
1979
- 1979-06-21 FR FR7915974A patent/FR2459240A1/fr active Granted
-
1980
- 1980-06-16 ES ES492484A patent/ES492484A0/es active Granted
- 1980-06-17 EP EP80400874A patent/EP0021973B1/fr not_active Expired
- 1980-06-17 AT AT81107653T patent/ATE4901T1/de not_active IP Right Cessation
- 1980-06-17 EP EP81107653A patent/EP0045980B1/fr not_active Expired
- 1980-06-17 DE DE8080400874T patent/DE3061266D1/de not_active Expired
- 1980-06-17 CA CA000354142A patent/CA1142936A/en not_active Expired
- 1980-06-18 AR AR281448A patent/AR229088A1/es active
- 1980-06-20 JP JP8300880A patent/JPS5636481A/ja active Pending
-
1981
- 1981-12-03 US US06/327,022 patent/US4409228A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA1142936A (en) | 1983-03-15 |
| EP0021973A2 (fr) | 1981-01-07 |
| EP0021973B1 (fr) | 1982-12-08 |
| ES8104274A1 (es) | 1981-04-16 |
| DE3061266D1 (en) | 1983-01-13 |
| EP0045980B1 (fr) | 1983-10-05 |
| AR229088A1 (es) | 1983-06-15 |
| EP0021973A3 (en) | 1981-04-29 |
| ES492484A0 (es) | 1981-04-16 |
| US4409228A (en) | 1983-10-11 |
| FR2459240B1 (cg-RX-API-DMAC10.html) | 1982-10-22 |
| ATE4901T1 (de) | 1983-10-15 |
| EP0045980A1 (fr) | 1982-02-17 |
| JPS5636481A (en) | 1981-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0021973B1 (fr) | Aminopipéridines anorexigènes, procédé pour leur préparation et médicaments les contenant | |
| EP0101381B1 (fr) | Trifluorométhylphényltétrahydropyridines à activité anorexigène, un procédé de préparation et compositions pharmaceutiques | |
| FR2645152A1 (fr) | 3h-pteridinones-4, procedes de preparation et medicaments les contenant | |
| EP0117779A1 (fr) | Dérivés de la pyridazine actifs sur le système nerveux central, procédé d'obtention et médicaments en contenant | |
| JP2010024243A (ja) | 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体 | |
| FR2720396A1 (fr) | Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| EP0254623A1 (fr) | Nouveaux dérivés amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procédés de préparation, médicaments les contenant, utiles notamment comme antalgiques | |
| EP0060179A1 (fr) | Compositions pharmaceutiques à action anorexigène | |
| EP1753725B1 (fr) | Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique | |
| CA1231950A (fr) | Procede d'obtention de nouveaux derives substitues du 2,5-diamino 1,4-diazole et des compositions pharmaceutiques en renfermant | |
| US5124328A (en) | Morpholine derivatives compositions and use | |
| US5077290A (en) | Morpholine derivatives compositions and use | |
| FR2547822A1 (fr) | Acylpiperazinoquinazolines substituees utiles comme medicaments et procede pour leur preparation | |
| EP0115714A1 (fr) | Composition pharmaceutique à action psychotrope dopanimergique | |
| FR2663929A1 (fr) | Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| EP0050072B1 (fr) | Nouvelles cyclopropylméthyl pipérazines, leur procédé de préparation et leur application en thérapeutique | |
| FR2501682A1 (fr) | Trifluoromethylphenylpyridines a activite anorexigene, un procede de preparation et compositions pharmaceutiques en contenant | |
| EP1146044B1 (fr) | Dérivés de cyclobuta-indole carboxamide agissant sur le système nerveux central, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| EP1187824B1 (fr) | Derives de [(2-substitue-5-[3-thienyl)-benzyl]-[2-([2-isopropoxy-5-fluoro]-phenoxy)-ethyl]-amine, leur procede de preparation et leur utilisation a titre de medicaments | |
| JPS6130588A (ja) | ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤 | |
| CA1207768A (fr) | Carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant | |
| FR2605008A1 (fr) | Derives d'imidazo (4,5-b)pyridinone-2, leur preparation et leur application en therapeutique | |
| WO1997020827A1 (fr) | Derives de fluorophenyl-triazines et pyrimidines comme composes actifs sur le snc | |
| EP0107536A1 (fr) | Benzo-et thiéno-triazine-1,2,3 ones-4, procédés de préparation et médicaments les contenant | |
| JPS61500613A (ja) | ２，６−ジオキソピペリジン誘導体、その製造法およびこれを含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |